S100A6 participates in initiation of autoimmune encephalitis and is under epigenetic control.
Chih-Hsiang LinSung-Chou LiMing-Hong LinChen-Jui HoYan-Ting LuYuyu LinPei-Hsien LinKuo-Wang TsaiMeng-Han TsaiPublished in: Brain and behavior (2023)
We clarified that S100A6 was under epigenetic regulation in patients with AE and that it helped B lymphocytes to adhere to and infiltrate the BBB endothelial layer, which could be counteracted by S100A6 antibodies. Therefore, the methylation profile of S100A6 could be a marker of the activity of AE, and countering the effect of S100A6 may be a potential treatment target for AE.